Alcon’s Suite Approach to Building the Premium Channel

As cataract patients’ expectations rise, demanding visual performance on par with refractive surgery, Alcon is striving to meet those high expectations through its Cataract Refractive Suite, Seba Leoni, vice president and global head, Surgical Suite for Alcon reported during the panel on diagnostics and the premium channel at OIS@ASCRS 2016. Leoni quoted results that showed…

Read More

Cassini Bets on Total Corneal Analysis to Drive Premium Channel

The key to growing the toric intraocular lens (IOL) sector for cataract surgery lies in obtaining more accurate measures of total corneal astigmatism, and Cassini thinks it has that key in its novel total corneal analysis (TCA), Chief Medical Officer Mark Packer, MD, said at OIS@ASCRS 2016. Cassini uses patented, colored, LED ray-tracing technology to…

Read More

IBMD Strives for Femto-like Capsulotomies Without the Cost

International Biomedical Devices (IBMD) is in preclinical investigation of its ApertureCTC precision capsulotomy device designed to achieve laser-like precision outcomes in cataract surgery, Chief Medical Officer Mark Packer, MD, reported at OIS@ASCRS 2016. The concept, Dr. Packer said, is to prevent “the heart-stopping capsulorhexis” while overcoming the challenges of “pricey” femtosecond laser-assisted cataract surgery, thus…

Read More

ClarVista Medical HARMONI Offers “Elegant Simplicity”

ClarVista Medical is a clinical-stage ophthalmic company that is introducing the HARMONI Modular IOL system to help surgeons navigate “the increasingly demanding environment of cataract surgery,” CEO Paul McLean said. Intraocular lens (IOL) design has not undergone a fundamental change in decades, but that’s about to change, he promised. “Until we can solve the dilemma…

Read More

Yeu on the Success of the Spotlight on the Premium Channel

Elizabeth Yeu, MD, led the “Spotlight on the Premium Channel” discussion at OIS@ASCRS 2016. In her session, representatives from AcuFocus, Bausch + Lomb, Abbott Medical Optics and Alcon shared information about their current and future pipelines. Dr. Yeu serves as a Corneal, Cataract and Refractive Surgeon at Virginia Eye Consultant and dedicates her time to…

Read More

From Mythbuster to Dealmaker

Barry Cheskin, CEO, president and co-founder of PowerVision, provides details on his company’s new partnership with Alcon. Video Highlights: 00:30 – Details on Alcon deal including investment and opportunity to acquire. 01:08 – Combination will help bring Fluidvision 2020 to market even sooner. 01:19 – The Power of OIS 01:25 – Were you looking for…

Read More

LensGen

OIS@ASCRS - Companies To Watch - LensGen (2016)

LensGen is a clinical stage company developing an accommodating IOL (AIOL) that mimics the natural human lens and uses the eye’s natural accommodative mechanism to change curvature and provide a continuous range of vision from distance to near. The LensGen AIOL has gone through an extensive design optimization and testing process over the last four…

Read More

PowerVision Shows `True Accommodation’

PowerVision has developed a fluid-controlled accommodating intraocular lens (IOL), the FluidVision AIOL, as the first platform to provide “true accommodation” by mimicking the eye’s natural accommodative process to transport fluids inside it, creating true shape change. “This is the first true shape-changing IOL system,” president, CEO, and co-founder Barry Cheskin said, and 36-month results are…

Read More

Close-Up Look at Progress in Surgical Presbyopia Correction

Close-Up Look at Progress in Surgical Presbyopia Correction - OIS News

Presbyopia, the age-related loss of accommodation and near/reading vision, typically begins at about age 40 and affects nearly everyone over age 50. This huge opportunity is inviting several companies to pursue disruptive approaches. Stephen Lane, MD, from the University of Minnesota, opened the Breakfast Breakout session at OIS@AAO with an overview of current presbyopia treatment…

Read More

FDA Looking to Follow Up on Year of “Firsts”

OIS@AAO - Breakfast with the FDA

If you’re an executive at an ophthalmic drug development company and desire a frank discussion on regulatory issues that are critical to your business, you’d certainly jump at the chance to invite to breakfast Wiley Chambers, MD, deputy director of the Division of Transplant and Ophthalmology Products within FDA’s Center for Drug Evaluation and Research.…

Read More

`Mythbuster’ Cheskin on Powervision’s Future Pipeline, Strength of IOLs

Barry Cheskin, co-founder, president, and CEO of PowerVision, introduces the company’s next iteration, Fluidvision 2020, a new IOL that doubles the power of accommodation for patients. PowerVision expects to have the IOL in clinics next year. Citing the lens’ clinical data, he also busts a myth about IOLs’ lifetime in the lens capsule. Speaking With:…

Read More

Tarantino on How AcuFocus Found Success Rolling Out KAMRA

Acufocus’ Nick Tarantino, Chief Global Clinical Research & Regulatory Affairs Officer, explains how AcuFocus is taking a “nice and measured” approach to rolling out its KAMRA inlay as a treatment for presbyopia. The KAMRA inlay received US approval on April 17, 2015, making it the first corneal inlay to achieve this landmark. Since approval, the…

Read More